Zobrazeno 1 - 10
of 378
pro vyhledávání: '"P, Gil Gil"'
Autor:
Bartomeu Fullana, Serafín Morales, Anna Petit, Ania Alay, Helena Verdaguer, Fina Climent, Valentí Navarro-Perez, Mónica Cejuela, Patricia Galvan, Anna Gumà, Antonio Llombart-Cussac, David Cordero, Oriol Casanovas, Aleix Prat, Miguel Gil-Gil, Sonia Pernas
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-8 (2024)
Abstract Neoadjuvant endocrine therapy (NET) for hormone receptor-positive (HR+) breast cancer might be as effective as chemotherapy, with a better toxicity profile. Blocking a crucial process such as angiogenesis with sunitinib may have a synergisti
Externí odkaz:
https://doaj.org/article/73d2bd5e8b3149adab539c333f43a859
Autor:
Teresa Gil-Gil, Brandon A. Berryhill, Joshua A. Manuel, Andrew P. Smith, Ingrid C. McCall, Fernando Baquero, Bruce R. Levin
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-9 (2024)
Abstract Traditionally, bacteriostatic antibiotics are agents able to arrest bacterial growth. Despite being traditionally viewed as unable to kill bacterial cells, when they are used clinically the outcome of these drugs is frequently as effective a
Externí odkaz:
https://doaj.org/article/b7e12236e76b4200921a0903c384a0e5
Autor:
Tomás Pascual, Aranzazu Fernandez-Martinez, Yash Agrawal, Adam D. Pfefferle, Nuria Chic, Fara Brasó-Maristany, Blanca Gonzàlez-Farré, Laia Paré, Guillermo Villacampa, Cristina Saura, Cristina Hernando, Montserrat Muñoz, Patricia Galván, Xavier Gonzàlez-Farré, Mafalda Oliveira, Miguel Gil-Gil, Eva Ciruelos, Patricia Villagrasa, Joaquín Gavilá, Aleix Prat, Charles M. Perou
Publikováno v:
npj Breast Cancer, Vol 10, Iss 1, Pp 1-11 (2024)
Abstract In this study, we performed genomic analyses of cell cycle and tumor microenvironment changes during and after ribociclib and letrozole or chemotherapy in the CORALLEEN trial. 106 women with untreated PAM50-defined Luminal B early breast can
Externí odkaz:
https://doaj.org/article/3f189cf1ef8a4f74a950d11ff22079b9
Autor:
Serena Di Cosimo, José Manuel Pérez-García, Meritxell Bellet, Florence Dalenc, Miguel J. Gil Gil, Manuel Ruiz-Borrego, Joaquín Gavilá, Elena Aguirre, Peter Schmid, Frederik Marmé, Joseph Gligorov, Andreas Schneeweiss, Joan Albanell, Pilar Zamora, Duncan Wheatley, Eduardo Martínez de Dueñas, Kepa Amillano, Eileen Shimizu, Miguel Sampayo-Cordero, Javier Cortés, Antonio Llombart-Cussac
Publikováno v:
Breast, Vol 76, Iss , Pp 103761- (2024)
Background: The capsule formulation of CDK4/6 inhibitor palbociclib has reduced solubility at gastric pH > 4.5 and may have decreased activity when used with proton-pump inhibitors (PPI). Herein, we report the effect of PPI on palbociclib capsule act
Externí odkaz:
https://doaj.org/article/d3b96315025744e9a531e42906d8d57a
Publikováno v:
Microbial Biotechnology, Vol 17, Iss 7, Pp n/a-n/a (2024)
Abstract Different international agencies recognize that antibiotic resistance is one of the most severe human health problems that humankind is facing. Traditionally, the introduction of new antibiotics solved this problem but various scientific and
Externí odkaz:
https://doaj.org/article/4e9b33d9f21d47beb7c5c844c09a93bd
Publikováno v:
Microbiology Spectrum, Vol 11, Iss 6 (2023)
ABSTRACT Pseudomonas aeruginosa is an opportunistic bacterial pathogen able to colonize a variety of habitats. Its success in colonizing these habitats relies on its metabolic robustness and its capability of efficiently using available carbon source
Externí odkaz:
https://doaj.org/article/6de143dca0e846b7bc1d824e849095c5
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Antibiotics, Vol 13, Iss 4, p 330 (2024)
Stenotrophomonas maltophilia is an opportunistic pathogen that produces respiratory infections in immunosuppressed and cystic fibrosis patients. The therapeutic options to treat S. maltophilia infections are limited since it exhibits resistance to a
Externí odkaz:
https://doaj.org/article/be3c37735b954ea6b18ff239f643797b
Autor:
S. Mouron, M. J. Bueno, A. Lluch, L. Manso, I. Calvo, J. Cortes, J. A. Garcia-Saenz, M. Gil-Gil, N. Martinez-Janez, J. V. Apala, E. Caleiras, Pilar Ximénez-Embún, J. Muñoz, L. Gonzalez-Cortijo, R. Murillo, R. Sánchez-Bayona, J. M. Cejalvo, G. Gómez-López, C. Fustero-Torre, S. Sabroso-Lasa, N. Malats, M. Martinez, A. Moreno, D. Megias, M. Malumbres, R. Colomer, M. Quintela-Fandino
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-18 (2022)
Phosphoproteomics is a promising tool for identifying biomarkers of treatment response in cancer. Here, the authors analyse proteomics profiling of HER2-negative female breast cancer patients and identify potential predictors of paclitaxel response.
Externí odkaz:
https://doaj.org/article/41967f5bfad84ad8ad25940b81837779
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.